Advances in rubidium PET and integrated imaging with CT angiography

The role of rubidium-82 (Rb-82) positron emission tomography (PET) in the evaluation and care of patients with suspected coronary artery disease is evolving in conjunction with advances in PET instrumentation, data analysis, and clinical research. Instrumentation developments such as three-dimensional acquisition, new scintillator materials, and x-ray CT help to improve the quality of Rb-82 images. New approaches to kinetic modeling and software tools for analysis of clinical Rb-82 studies are being developed and evaluated, enabling quantification of absolute myocardial blood flow and flow reserve. Recent clinical research studies are providing new insights into the value of Rb-82 cardiac imaging compared with single photon emission CT myocardial perfusion imaging. Integrated x-ray CT angiography and Rb-82 PET perfusion imaging on hybrid PET/CT systems is an exciting new prospect. Complementary anatomical and functional information on atherosclerosis and ischemia can be provided in a single imaging session for better diagnosis and risk stratification of patients with coronary artery disease.     

Recent advances in cardiac positron emission tomography in the clinical management of the cardiac patient

Despite being primarily a research tool, positron emission tomography (PET) has seen slow but steady growth in the clinical management of the cardiac patient. The two major clinical applications of cardiac PET are regional myocardial perfusion imaging to determine the presence and severity of coronary artery disease and metabolic imaging to differentiate viable from nonviable myocardium in patients with ischemic left ventricular dysfunction. Indeed, PET with either nitrogen 13 ammonia or rubidium 82 may offer advantages over current single photon emission computed tomography approaches to assess myocardial perfusion. PETwith fluorine 18 fluorodeoxyglucose is considered the current gold standard for identifying viable myocardium. Finally, the use of PET to quantify myocardial perfusion, metabolism, and innervation has led to key insights into the role of altered microvascular function, substrate metabolism, and neuronal function in a variety of cardiac disease processes.     

Untersuchung der Myokardperfusion mit der Positronen-Emissions-Tomographie

Positron emission tomography (PET) of the heart has gained widespread scientific and clinical acceptance with regard to two indications: 1) The detection of perfusion abnormalities by qualitative and semiquantitative analyses of perfusion images at rest and during physical or pharmacological stress using well-validated perfusion tracers, such as N-13 ammonia, Rb-82 rubidium chloride, or O-15 labeled water. 2) Viability imaging of myocardial regions with reduced contractility by combining perfusion measurements with substrate metabolism as assessed from F-18 deoxyglucose utilization. This overview summarizes the use of PET as a perfusion imaging method. With a sensitivity > 90% in combination with high specificity, PET is today the best-validated available nuclear imaging technique for the diagnosis of coronary artery disease (CAD). The short half-life of the perfusion tracers in combination with highly sophisticated hard- and software enables rapid PET studies with high patient throughput. The high diagnostic accuracy and the methological advantages as compared to conventional scintigraphy allows one to use PET perfusion imaging to detect subtle changes in the perfusion reserve for the detection of CAD in high risk but asymptomatic patients as well as in patients with proven CAD undergoing various treatment forms such as risk factor reduction or coronary revascularization. In patients following orthotopic heart transplantation, evolving transplant vasculopathy can be detected at an early stage. Quantitative PET imaging at rest allows for detection of myocardial viability since cellular survival is based on maintenance of a minimal perfusion and structural changes correlate to the degree of perfusion reduction. Furthermore, quantitative assessment of the myocardial perfusion reserve detects the magnitude and competence of collaterals in regions with occluded epicardial collaterals and, thus, imaging of several coronary distribution territories in one noninvasive study. The cost of PET in combination with the cost of a cyclotron facility together with the demanding methological problems have limited the availability of perfusion PET to a few sophisticated centers. Therefore, quantitative PET investigations of myocardial perfusion have been performed predominantly for scientific purposes, and the cost-effectiveness of PET in the everyday clinical setting is not yet finally proven. However, the unique possibilities of PET to study non-invasively and quantitatively myocardial perfusion and metabolism as well as cardiac innervation and pharmacokinetics of cardiac drugs have established cardiac PET as a scientific tool of the highest quality for the future.     

Positron emission tomography and molecular imaging

The use of positron emission tomography (PET) in cardiology is growing rapidly. Technical features make PET a strong technology for the non-invasive evaluation of cardiac physiology. It is currently considered the most reliable tool for the identification of myocardial viability and also allows accurate assessment of myocardial perfusion and detection of coronary artery disease (CAD). The unique feature of PET is that myocardial perfusion can be measured in absolute terms, improving sensitivity in the detection of multivessel of disease and also allowing evaluation of very early changes in coronary vasoreactivity and the progression or regression of CAD. Use of the newest generation of PET systems with integrated multislice computed tomography (CT) is becoming a standard technique for cardiac imaging. Since the PET and CT techniques ideally complement each other the combination is particularly attractive for the non-invasive assessment of CAD but also has other functions. Finally, there are also promising future applications that involve molecular imaging of cardiac targets, which may further enhance the clinical utility of PET and hybrid imaging.     

MRI for the diagnosis of myocardial ischemia and viability

Assessment of myocardial ischemia and viability plays a crucial role in the clinical management of patients with coronary artery disease. Recently, cardiovascular MRI has emerged as an important noninvasive diagnostic modality in the assessment of coronary artery disease. MRI is able to evaluate both myocardial perfusion as well as myocardial contractile reserve. Because of its superior spatial resolution, integration of qualitative and quantitative methodology, and excellent reproducibility, MRI has advantages over conventional noninvasive modalities currently used in the evaluation of myocardial ischemia and viability, and may well emerge as the premier noninvasive technique in the assessment of patients with coronary artery disease. The authors review the rapidly expanding recent literature that has now established cardiovascular MRI (including dobutamine cine MRI and vasodilator perfusion MRI techniques) as an ideal choice in the evaluation of myocardial ischemia and delayed contrast-enhanced MRI and low-dose dobutamine cine MRI for evaluation of viability. Comparisons with more established techniques such as dobutamine stress echocardiography, single photon emission computed tomography perfusion imaging, and positron emission tomography are reviewed.     

Potential impact of noncontrast computed tomography as gatekeeper for myocardial perfusion positron emission tomography in patients admitted to the chest pain unit

We investigated the ability of coronary artery calcium (CAC) to predict a normal adenosine stress rubidium-82 (Rb-82) myocardial perfusion positron emission tomography (PET) in patients admitted to the chest pain unit. Eighty-four consecutive patients (33 men; mean age 62 +/- 14.8 years) with low to intermediate likelihood of coronary artery disease were included. A single noncontrast computed tomogram under shallow breathing was obtained for attenuation correction and to assess the presence of CAC. This was followed by a rest and adenosine stress dynamic Rb-82 emission PET. Computed tomography and PET images were interpreted independently. There was a high prevalence of risk factors (80% hypertension, 30% diabetes, 38% hypercholesterolemia, 13% smoking); prior coronary revascularization and myocardial infarction were present in 21% and 15% of the patients, respectively. The absence of CAC was associated with a normal adenosine stress Rb-82 myocardial perfusion PET in 34 of 34 patients, yielding a negative predictive value of 100%. The presence of CAC (50 of 84) was associated with a higher incidence of myocardial perfusion defects (13 of 50), yielding a positive predictive value of 26%. Sensitivity was 100% (13 of 13) and specificity was 48% (34 of 71). In conclusion, the absence of CAC is predictive of a normal adenosine stress Rb-82 myocardial perfusion PET in patients admitted to the chest pain unit. If these results are confirmed, myocardial perfusion imaging probably can be safely avoided in chest pain patients with negative CAC with low to intermediate pretest likelihood of disease. This approach may decrease overall radiation exposure and hospital time and prove to be cost effective.     

Assessment of Ischemic Heart Disease Using Magnetic Resonance First-Pass Perfusion Imaging

METHODS: Cardiovascular magnetic resonance (MR) perfusion imaging has matured to a point where it can be routinely applied to assess patients with coronary artery disease and ischemic cardiomyopathy. The method has been compared to invasive, catheter-based as well as other noninvasive imaging modalities (echocardiography, single-photon emission computed tomography [SPECT], and positron emission tomography [PET]) for the evaluation of patients with coronary artery disease. Besides qualitative evaluation of MR perfusion images, an absolute quantification of global, regional and transmural myocardial perfusion is possible. A relative or absolute myocardial perfusion reserve has been determined noninvasively with MR perfusion imaging, and can provide good agreement with the invasive assessment. Based on the perfusion reserve, the severity of an epicardial coronary stenosis can be evaluated in patients with known or suspected coronary artery disease. Besides the absence of radiation exposure, MR perfusion imaging offers good temporal and excellent spatial resolution. In particular, the spatial resolution increases the sensitivity and specificity for the detection of coronary artery disease. New parameters such as the "endo-/epimyocardial resting perfusion ratio", may under some circumstances sufficiently enhance the sensitivity for detecting an abnormal perfusion, and thus avoid potentially harmful and expensive stress testing in patients with suspected ischemic heart disease. New revascularization modalities such as therapeutic angiogenesis need to be matched by sensitive imaging tools to prove their benefits. Thus, the optimization of therapeutic angiogenesis may profit from the diagnostic advantages provided by MR perfusion imaging. Furthermore, MR might yield new insights into the pathophysiology of cardiac diseases such as "syndrome X", or might help in the repetitive assessment of heart transplant recipients, possibly obviating the need for further invasive testing. CONCLUSION: The breadth of cardiac MRI allows the combined noninvasive assessment of myocardial perfusion, function, as well as myocardial viability. The combination gives MRI a unique and strong position in the field of noninvasive diagnostic cardiology.     

Positron emission tomography in ischemic heart disease

Non-invasive assessment of ischemic heart disease remains a challenging task, even with a large armory of diagnostic modalities. Positron emission tomography (PET) is an advanced radionuclide technique that has been available for decades. Originally used as a research tool that contributed to advances in the understanding of cardiovascular pathophysiology, it is now becoming established in clinical practice and is increasingly used in the diagnosis and risk stratification of patients with ischemic heart disease. PET myocardial perfusion imaging has a mean sensitivity and specificity of around 90% for the detection of angiographically significant coronary artery disease, and is also highly accurate for assessing the prognosis of patients with ischemic heart disease. Depending on the radiotracer used, it can provide information not only on myocardial perfusion but also on myocardial metabolism, which is essential for viability assessment. The potential of this imaging technique has been further increased with the introduction of hybrid scanners, which combine PET with computed tomography or cardiac magnetic resonance imaging, offering integrated morphological and functional information and hence comprehensive assessment of the effects of atherosclerosis on the myocardium. The scope of this review is to summarize the role of PET in ischemic heart disease.     

Myocardial perfusion imaging in ischemic heart disease anno 1990

The field of radionuclide myocardial perfusion imaging is in a rapid state of change. Stress-rest myocardial imaging is important not only for the detection of coronary artery disease but also for prognostic stratification of patients. In particular, assessment of myocardial viability in patients with left ventricular dysfunction is a recent focus of investigation. Single-photon emission computed tomography has become widely accepted as the preferred (albeit challenging) imaging modality for myocardial perfusion imaging. Silent myocardial ischemia and its clinical significance continues to be an intriguing aspect of the clinical manifestation of coronary artery disease. Myocardial perfusion imaging is an invaluable independent method to unravel this problem. Dipyridamole was approved for pharmacologic vasodilation in conjunction with myocardial perfusion imaging. At the same time, direct infusion of adenosine was proposed as an alternative method of effecting vasodilatory stress. In 1990, several new technetium-99m-labeled myocardial perfusion imaging agents have been introduced (teboroxime and hexakis-2-methoxyisobutyl-isonitrile [sestaMIBI]) that may have a profound impact on imaging techniques and applications of myocardial perfusion imaging.     

SPECT Imaging for Detecting Coronary Artery Disease and Determining Prognosis by Noninvasive Assessment of Myocardial Perfusion and Myocardial Viability

Basic knowledge of active and passive transport mechanisms for concentrating monovalent cations in myocardial cells led to the investigation of the application of radioisotopes of potassium, thallium, rubidium, and ammonia to the in vivo noninvasive assessment of regional myocardial perfusion and viability utilizing gamma camera or positron emission tomographic (PET) imaging technology. Subsequently, technetium-99m (Tc-99m)-labeled isonitriles (sestamibi and tetrofosmin), which bind to mitochondrial membranes, emerged as superior imaging agents with single photon emission tomography (SPECT) imaging. When any of these imaging agents are injected intravenously during either exercise or pharmacologic stress, myocardial defects in tracer uptake represent either abnormal regional flow reserve or myocardial scar reflecting of coronary artery disease (CAD). The major clinical indications for stress SPECT or PET myocardial perfusion imaging are for detection of CAD as the cause of chest pain and risk stratification for prognostication. Patients with normal stress myocardial perfusion scans have an excellent prognosis with <1.0% annual rate future annual death or nonfatal infarction. The greater the extent and severity of ischemic perfusion defects (defects seen on stress images but improve on resting images), the greater the subsequent death or infarction rate during follow-up. Rest imaging alone is performed for determination of myocardial viability in patients with CAD and severe left ventricular dysfunction. Myocardial segments showing >50% uptake compared to normal uptake have a better long-term outcome with revascularization than with medical therapy with enhanced left ventricular function and improved survival. Other applications of SPECT imaging include the evaluation of cardiac sympathetic function, assessment of myocardial metabolism in health and disease, and molecular imaging of coronary atherosclerosis and myocardial stem cell therapy.     

Usefulness and pitfalls in myocardial perfusion SPECT for detecting and assessing coronary artery disease

Thallium-201(Tl) is the dominant agent employed for myocardial perfusion imaging for detection of coronary artery disease, assessment of myocardial viability and prognostication. Technetium-99m(Tc) labeled radionuclides have been used as excellent alternatives to Tl. This paper will review the usefulness and pitfall in myocardial perfusion single photon emission computed tomography(SPECT) in patients with coronary artery disease. From a practical standpoint, we should know what are clinical questions, clinical status of patients(history and exercise ability of patients, obesity) and diagnostic accuracy of each diagnostic protocol and the performance in the nuclear laboratory. Myocardial perfusion defects during stress SPECT are produced by a heterogeneity in coronary blood flow, which depends on severity of coronary stenosis and consequent abnormalities in flow reserve. Certain factors can affect sensitivity and specificity of Tl SPECT for detection of coronary artery disease. Accurate determination of myocardial viability is vitally important for clinical decision making for patients with left ventricular(LV) dysfunction who will most benefit from revascularization. Hibernated myocardium may result in profound regional LV dysfunction in absence of necrosis. The various approach such as stress-redistribution-reinjection imaging, rest-redistribution imaging and rest-redistribution 24 hours delayed imaging has been utilized to assess myocardial viability with Tl. Alternatively, quantitative assessment of 99mTc-methoxy-isobutyl isonitrile(MIBI) and tetrofosmin uptake reflect the degree of viability. At the present time one of the most important clinical applications of exercise myocardial perfusion SPECT is the assessment of prognosis for patients with suspected and documented coronary artery disease. Patients with normal stress perfusion SPECT have a low event rate and excellent prognosis. Stress perfusion imagings have been widely used to stratify patients into different risk groups in the United State.     

Assessing viable myocardium with thallium-201.

Patients with chronic coronary artery disease and potentially reversible left ventricular dysfunction can often be successfully identified by one or more clinical indicators of myocardial viability, including regional wall motion, systolic wall thickening, regional myocardial perfusion as determined by perfusion tracers, and redistribution of thallium-201. In some patients, however, viable but "hibernating" myocardium will exist even when none of the above are evident. Myocardial viability in this situation can be detected with a high degree of accuracy by the demonstration of preserved metabolic activity by positron emission tomography (PET) scanning. Additionally, modifications of the standard exercise-redistribution thallium protocol may also produce accurate results. These modifications include late thallium-201 redistribution imaging, performed 8-72 hours following initial thallium injection, and thallium reinjection at rest after early (3-4 hours) or late (8-72 hours) redistribution imaging. These methods can identify viable myocardium in many thallium defects that appear to be irreversible on a standard 3-4 hour redistribution image. In addition, serial imaging after administration of thallium-201 at rest may also provide valuable insights into myocardial viability. These imaging modalities have important practical applications in the evaluation and management of patients with coronary artery disease and left ventricular dysfunction.     

Magnetic resonance imaging in the assessment of coronary artery disease

Magnetic resonance imaging (MRI) is gaining importance in cardiology as the noninvasive test of choice for patients with a multitude of cardiovascular problems. Recently, cardiovascular MRI has emerged as an important noninvasive diagnostic modality in the assessment of coronary artery disease. Because of its superior spatial resolution, integration of qualitative and quantitative methodology, and excellent reproducibility, MRI has advantages over conventional noninvasive modalities currently used in the evaluation of coronary artery disease. This article reviews the rapidly expanding recent literature that has now established cardiovascular MRI as an ideal choice in the evaluation of myocardial ischemia (including dobutamine cine MRI and vasodilator perfusion MRI techniques). We further discuss the role of delayed contrast-enhanced MRI and low-dose dobutamine cine MRI for evaluation of myocardial viability. Comparisons with more established techniques, such as dobutamine stress echocardiography, single-photon emission computed tomography perfusion imaging, and positron emission tomography, are reviewed.     

Assessment of myocardial viability with myocardial contrast echocardiography

The application of noninvasive imaging techniques to assess myocardial viability has become an important part of routine management of patients with acute myocardial infarction and chronic coronary artery disease. Information regarding the presence and extent of viability may help identify patients likely to benefit from revascularization or therapy directed at attenuating left ventricular remodeling. Myocardial contrast echocardiography (MCE) is capable of defining the presence and extent of viability by providing an accurate assessment of microvascular integrity needed to maintain myocellular viability. It is especially suited for the spatial assessment of perfusion, even when myocardial blood flow is reduced substantially in the presence of severe epicardial stenoses or in a bed dependent on collateral perfusion. The routine use of MCE to evaluate viability in patients with acute and chronic coronary artery disease is now feasible with the advent of new imaging technologies and microbubble agents capable of myocardial opacification from venous injections. The utility of this technique for determining treatment strategies has not been established but is forthcoming.     

Multimodality Imaging for Assessment of Myocardial Viability: Nuclear,Echocardiography, MR,and CT

The assessment of myocardial viability may be an important component of the evaluation of patients with coronary artery disease and left ventricular dysfunction. The primary goal of viability assessment in such patients is to guide therapeutic decisions by determining which patients would most likely benefit from revascularization. In patients with chronic coronary artery disease, left ventricular dysfunction may be a consequence of prior myocardium infarction, which is an irreversible condition, or reversible ischemic states such as stunning and hibernation. Imaging techniques utilize several methods to assess myocardial viability: left ventricular function, morphology, perfusion, and metabolism. Each technique (echocardiography, nuclear imaging, magnetic resonance imaging, and x-ray computed tomography) has the ability to assess one or more of these parameters. This article describes how each of these imaging modalities can be used to assess myocardial viability, and reviews the relative strengths and limitations of each technique.     

Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82

The purpose of this study was to determine the clinical feasibility of diagnosing significant coronary artery disease by positron imaging of myocardial perfusion without a cyclotron, using generator-produced rubidium-82 (82Rb). Fifty patients underwent positron emission tomography of the entire heart using a multislice positron camera and intravenous 82Rb or nitrogen-13 ammonia (13NH3) before and after intravenous dipyridamole combined with handgrip stress. Images were read by two observers blinded as to clinical or arteriographic data. Automated quantitative coronary arteriography was obtained for the arteriographic determination of coronary flow reserve, previously demonstrated to be a single integrated measure of stenosis severity accounting for all its geometric dimensions of length, absolute diameter, percent narrowing and asymmetry by quantitative analysis of cine films. Significant coronary artery disease was defined as an arteriographically determined coronary flow reserve of less than 3.0 based on all stenosis dimensions. Any single geometric measure of stenosis severity alone was an inadequate reference standard for comparison with perfusion images. Sensitivity of identifying patients with coronary artery disease having an arteriographically determined coronary flow reserve of less than 3.0 was 95% by positron imaging with a specificity of 100%. The single case that was missed, studied with 13NH3, had a 43% diameter narrowing of a small ramus intermedius off the left coronary artery with no significant narrowing of the major coronary arteries. Positron emission tomography of myocardial perfusion before and after intravenous dipyridamole combined with handgrip stress utilizing generator-produced 82Rb provides sensitive and specific diagnosis of reduced coronary flow reserve due to coronary artery disease in humans.     

Comparison of treadmill exercise versus dipyridamole stress with myocardial perfusion imaging using rubidium-82 positron emission tomography

OBJECTIVES: This study assessed the feasibility of treadmill exercise rubidium-82 ((82)Rb) positron emission tomography (PET) and compared image quality and diagnostic content with dipyridamole (82)Rb PET in patients referred for evaluation of coronary artery disease (CAD). BACKGROUND: Dipyridamole stress (82)Rb PET myocardial perfusion imaging (MPI) is an accurate imaging modality used to diagnose CAD and determine prognosis. Although pharmacologic stress is used routinely, exercise treadmill stress may be an alternative and provide clinical information helpful to decision making, particularly for patients unwilling or unable to tolerate pharmacologic stress. METHODS: Fifty patients (mean age, 60 +/- 10 years; 47 men) underwent treadmill exercise and dipyridamole (82)Rb PET. Images were assessed: 1) qualitatively using a 17-segment model and a semiquantitative visual score on a five-point scale and with calculation of summed stress score (SSS), summed rest score (SRS), and summed difference score (SDS); and 2) quantitatively with a 70% threshold for abnormal perfusion and expressed as extent of abnormal perfusion (% left ventricular). RESULTS: Treadmill exercise was preferred by 74% of patients (37 of 50, p < 0.001). The exercise and dipyridamole (82)Rb PET summed scores and quantitative extent of abnormal perfusion were very similar and highly correlated. Results of Bland-Altman analysis showed no significant bias. Image quality was superior with exercise stress with greater myocardial uptake and higher target to background ratios. CONCLUSIONS: Treadmill exercise (82)Rb PET is feasible and provides imaging results of similar diagnostic content and superior image quality compared with dipyridamole stress. Treadmill exercise is a reasonable alternative to pharmacologic stress with (82)Rb PET MPI.     

Assessment of myocardial perfusion and viability by Positron Emission Tomography

An important evolution has taken place recently in the field of cardiovascular Positron Emission Tomography (PET) imaging. Being originally a highly versatile research tool that has contributed significantly to advance our understanding of cardiovascular physiology and pathophysiology, PET has gradually been incorporated into the clinical cardiac imaging portfolio contributing to diagnosis and management of patients investigated for coronary artery disease (CAD). PET myocardial perfusion imaging (MPI) has an average sensitivity and specificity around 90% for the detection of angiographically significant CAD and it is also a very accurate technique for prognostication of patients with suspected or known CAD. In clinical practice, Rubidium-82 (⁸²Rb) is the most widely used radiopharmaceutical for MPI that affords also accurate and reproducible quantification in absolute terms (ml/min/g) comparable to that obtained by cyclotron produced tracers such as Nitrogen-13 ammonia (¹³N-ammonia) and Oxygen-15 labeled water (¹⁵O-water). Quantification increases sensitivity for detection of multivessel CAD and it may also be helpful for detection of early stages of atherosclerosis or microvascular dysfunction. PET imaging combining perfusion with myocardial metabolism using ¹⁸F-Fluorodeoxyglucose (¹⁸F FDG), a glucose analog, is an accurate standard for assessment of myocardial hibernation and risk stratification of patients with left ventricular dysfunction of ischemic etiology. It is helpful for guiding management decisions regarding revascularization or medical treatment and predicting improvement of symptoms, exercise capacity and quality of life post-revascularization. The strengths of PET can be increased further with the introduction of hybrid scanners, which combine PET with computed tomography (PET/CT) or with magnetic resonance imaging (PET/MRI) offering integrated morphological, biological and physiological information and hence, comprehensive evaluation of the consequences of atherosclerosis in the coronary arteries and the myocardium.     

Integrated PET/CT in the assessment of etiology and viability in ischemic heart failure

About 5.3 million people in the United States suffer from heart failure, the cause of which in many patients is atherosclerotic coronary artery disease. The clinical prognosis in patients with ischemic heart failure is worse than in those with a nonischemic etiology, but the former can potentially be improved with revascularization. Integrated positron emission tomography/computed tomography (PET/CT) scanners provide a unique opportunity for determining the cause of heart failure by integrating anatomic and functional imaging of coronary circulation and heart anatomy in a single study. Several studies have shown that a combined approach of coronary CT angiography and PET-assisted myocardial perfusion imaging can accurately evaluate coronary artery disease as the underlying cause of chronic and new-onset heart failure. PET viability testing can reveal the amount of functional myocardium and help in selecting a therapeutic strategy in patients with heart failure. Even though properly conducted prospective randomized trials are still lacking, PET/CT may become the method of choice for initial evaluation and management of patients with heart failure.     

Update in nuclear cardiology

Imaging techniques for the noninvasive detection and evaluation of coronary artery disease continue to develop. New techniques for the quantification of myocardial blood flow by positron-emission tomography, new approaches to metabolic imaging, and new gamma camera technology have the potential to expand the scope of cardiac nuclear medicine in many facilities. Determination of the best and most cost-effective method of assessing myocardial viability in patients with advanced coronary artery disease remains of key interest with research directed at alternative 201Tl imaging protocols, fatty acid metabolism, and viability assessment with the new 99mTc-based myocardial perfusion radiopharmaceuticals. The assessment of endothelial function and determination of coronary flow reserve with 13N-ammonia positron-emission tomography may aid in the identification of preclinical atherosclerosis, and in monitoring disease progression and response to therapy. New information in radionuclide perfusion imaging in young and elderly patients and in those with interventricular conduction disturbances may allow for more accurate identification of coronary artery disease. The role of radionuclide imaging in patients with dilated cardiomyopathy continues to evolve with the development of radiolabeled chemicals of the adrenergic nervous system and their analogues, which will be helpful in the stratification of disease severity. These new imaging techniques promise to increase the accuracy of nuclear cardiology for detection of disease, assessment of function, and prognosis.